The nutraceutical effect of Scenedesmus dimorphus for obesity and nonalcoholic fatty liver disease–linked metabolic syndrome

ABSTRACT

Obesity is a major cause of nonalcoholic fatty liver disease (NAFLD), which is identified as a characteristic relatedto metabolic syndrome. This study focuses on the benefits of Scenadesmus dimorphus as a nutraceutical to overcomeNAFLD-linked metabolic syndrome caused by obesity. The research used 30 mice (Mus musculus) divided into sixgroups normal control, obesity control (OC), and drug control (Orlistat) and S. dimorphus administrated orally for21 days in obese mice with NAFLD-linked metabolic syndrome with doses of 5 mg/20 g body weight (BW), 10mg/20 g BW, and 15 mg/20 g BW. The administration of a high-fat diet can cause obese mice to suffer from NAFLD,resulting in an increase in liver enzymes and changes in lipid metabolism. Administration of S. dimorphus at 15mg/20 g BW decreases the activity of liver enzymes and improves liver function. The statistics test showed significantdifferences (p < 0.05 analysis of variance) to decrease the liver enzyme activity of alanine aminotransferase, aspartateaminotransferase, and alkaline phosphatase compared to OCs. Administration of S. dimorphus resulting in metabolismchanges showed a significant (at p < 0.05) decrease in total cholesterol, triglycerides, and low-density lipoproteincholesterol and increased high-density lipoprotein cholesterol. Microalgae S. dimorphus is beneficial as a nutraceuticalto manage obesity and reverse NAFLD-linked metabolic syndrome in obese mice.